The growing need for effective dermatological treatments and increasing awareness of viral skin infections are supporting the expansion of the global molluscum contagiosum market. The condition, caused by the molluscum contagiosum virus, commonly affects children and can also occur in adults. Its contagious nature and potential for persistent skin lesions are encouraging demand for treatment options that address symptoms, reduce transmission, and improve patient outcomes.

According to Straits Research, the global molluscum contagiosum market was valued at USD 2.53 billion in 2025 and is projected to increase from USD 2.65 billion in 2026 to USD 3.84 billion by 2034, registering a CAGR of 4.75% during the forecast period 2026–2034. Continued research into topical medications and other treatment approaches is expected to create opportunities for pharmaceutical companies and dermatology care providers.

Rising Infection Incidence Supports Treatment Demand

Molluscum contagiosum is a common viral skin infection characterized by small, raised, flesh-colored or pink lesions, often with a central indentation. The infection spreads through direct skin contact and contaminated objects, including towels and clothing. Children, sexually active adults, and individuals with weakened immune systems are among the populations affected.

Although the condition can resolve naturally over time, medical intervention may be considered when lesions spread, cause discomfort, or create cosmetic concerns. Increasing awareness of available treatment options and the need to manage persistent or extensive infections are supporting demand across dermatology clinics and healthcare facilities.

Topical Therapies Dominate the Treatment Landscape

Topical therapies represent the leading treatment segment in the molluscum contagiosum market. These treatments target skin lesions directly and include agents such as cantharidin, podophyllotoxin, salicylic acid, tretinoin, and imiquimod. Their non-invasive administration and suitability for localized treatment support their use in dermatological care.

Cantharidin has gained particular attention following the introduction of an FDA-approved treatment for molluscum contagiosum. YCANTH, developed by Verrica Pharmaceuticals, uses a topical cantharidin formulation delivered through a single-use applicator. The availability of a regulated treatment option has strengthened the commercial landscape for prescription-based dermatological therapies.

Research and Development Expand Treatment Opportunities

Pharmaceutical companies are exploring improved treatment options that can address the limitations of existing approaches. Research is focused on developing therapies that offer convenient administration, effective lesion clearance, and improved patient tolerability.

Immune-modulating therapies are another part of the treatment landscape, while cryotherapy and curettage remain established procedural approaches. Cryotherapy uses controlled freezing to destroy affected tissue, whereas curettage involves physically removing lesions. The choice of treatment depends on factors such as lesion distribution, patient age, clinical circumstances, and healthcare provider assessment.

Japan's YCANTH Launch Strengthens International Market Access

A notable development occurred on February 9, 2026, when Verrica Pharmaceuticals announced the commercial launch of YCANTH in Japan through its partner Torii Pharmaceutical. The launch followed Japanese regulatory approval and expanded access to the cantharidin-based treatment beyond the United States.

In May 2026, Verrica reported continued commercial progress for YCANTH, including a 51.3% year-over-year increase in dispensed applicator units during the first quarter of 2026. The company also reported that the product had exceeded 100,000 dispensed applicator units since its U.S. launch. These developments highlight the growing commercial relevance of prescription topical therapies in the dermatology market.

North America Leads the Molluscum Contagiosum Market

North America accounted for 41.6% of the global molluscum contagiosum market in 2025, supported by established healthcare infrastructure, access to dermatological services, and the availability of advanced treatment options. The United States represents a major contributor, with molluscum contagiosum affecting children and adults across the country. FDA approval of YCANTH in July 2023 also strengthened the region's prescription treatment landscape.

Asia Pacific offers additional growth opportunities as healthcare awareness and access to dermatological treatments expand. Population density, changing lifestyles, and increasing clinical research activity contribute to the region's market potential. Japan's introduction of YCANTH in February 2026 represents an important development in the availability of specialized molluscum contagiosum treatment across the region.

Competitive Landscape and Key Market Participants

The competitive landscape includes pharmaceutical companies developing and commercializing therapies for dermatological conditions. Key participants identified by Straits Research include Verrica Pharmaceuticals, Novan Inc., Veloce BioPharma LLC, and Gurina Foundation.

Verrica Pharmaceuticals holds an important position through YCANTH, its cantharidin-based topical treatment. The company's commercial partnerships and international expansion activities highlight the importance of product approvals, distribution agreements, and clinical development in strengthening market presence. Future competition is expected to reflect treatment accessibility, clinical performance, regulatory progress, and the development of convenient therapeutic options.

Future Outlook

The molluscum contagiosum market is expected to experience steady growth as awareness of viral skin infections and access to dermatological treatments improve. Topical therapies are likely to remain important, while pharmaceutical research and international product launches create additional opportunities. With the market projected to reach USD 3.84 billion by 2034, treatment innovation and broader healthcare access will continue to shape the industry's development.

Explore the full market report: https://straitsresearch.com/report/molluscum-contagiosum-market

About Straits Research

Straits Research is a market intelligence and consulting firm providing industry analysis, market sizing, competitive assessments, and strategic insights across global industries. Its research supports businesses and decision-makers in identifying market opportunities and making informed strategic decisions.